Dorsal Root Ganglion Stimulation for the Management of Intractable Painful Polyneuropathy: A Prospective Pilot Study. Issue 4 (19th December 2020)

• Record Type: Journal Article
• Authors: Koetsier, Eva; van Kuijk, Sander M.J.; Melli, Giorgia; Dukanac, Jasmina; Barbero, Marco; van Zundert, Jan; Joosten, Elbert A.; Maino, Paolo
• Is Part Of: Neuromodulaton. Volume 24:Issue 4(2021)
• Page Start: 685
• Page End: 694
• Publication Date: 2020-12-19
• Subjects: Dorsal root ganglion stimulation -- painful polyneuropathy -- peripheral neuropathy; Central nervous system -- Physiology -- Periodicals; Central nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ner.13336
• Languages: English
• ISSNs: 1094-7159

Abstract

Abstract: Objectives: Dorsal root ganglion stimulation (DRGS) is a promising neurostimulation modality in the treatment of painful polyneuropathy. The aim of this prospective pilot study was to investigate the effect of DRGS on pain intensity in patients with intractable painful polyneuropathy. Materials and Methods: Nine patients with chronic, intractable painful polyneuropathy in the lower limbs were recruited. In each subject, between two and four DRGS leads were placed at the level of the L5 and S1 dorsal root ganglion. If trial stimulation was successful, a definitive implantable pulse generator (IPG) was implanted. Pain intensity was scored using an 11‐point numeric rating scale (NRS) and reported as median and interquartile range (IQR), and compared to baseline values using the Wilcoxon signed‐rank test. Additionally, patients' global impression of change (PGIC), pain extent, presence of neuropathic pain, physical functioning, quality of life, and mood were assessed. Results: Eight out of nine patients had a successful trial phase, of which seven received an IPG. Daytime pain decreased from a median (IQR) NRS score of 7.0 (5.9–8.3) to 2.0 (1.0–3.5) and 3.0 (1.6–4.9) in the first week and at six months after implantation, respectively. Similar effects were observed for night time and peak pain scores. Conclusions: The results of this study suggest that DRGS significantly reduces both pain intensity and PGIC in patients with intractable painful polyneuropathy in the lower extremities. Large‐scale clinical trials are needed to prove the efficacy of DRGS in intractable painful polyneuropathy.